Literature DB >> 14870910

The NIH pulse cyclophosphamide regime: the end of an era?

Y Karim, D P D'Cruz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14870910     DOI： 10.1191/0961203304lu524ed

Source DB:  PubMed          Journal:  Lupus        ISSN： 0961-2033            Impact factor:   2.911


× No keyword cloud information.
  3 in total

Review 1.  Oral cyclophosphamide is on the verge of extinction as therapy for severe autoimmune diseases (especially lupus): should nephrologists care?

Authors:  Lee A Hebert; Brad H Rovin
Journal:  Nephron Clin Pract       Date:  2010-08-03

2.  Successful treatment of class V+IV lupus nephritis with multitarget therapy.

Authors:  Hao Bao; Zhi-Hong Liu; Hong-Lang Xie; Wei-Xin Hu; Hai-Tao Zhang; Lei-Shi Li
Journal:  J Am Soc Nephrol       Date:  2008-07-02       Impact factor: 10.121

3.  CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice.

Authors:  Olivia Weigert; Caroline von Spee; Reinmar Undeutsch; Lutz Kloke; Jens Y Humrich; Gabriela Riemekasten
Journal:  Arthritis Res Ther       Date:  2013-02-27       Impact factor: 5.156
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.